Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

In a 1 a.m. Eastern time press release, Regeneron said one Phase 3 trial of itepekimab, in adult former smokers with COPD, met the primary target by showing significant reduction of 27% in the sudden ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...